News about Global Pharma

INCOR Group and Renovis Labs forms JV

INCOR Renovis Pharma has come up with a new innovative methodology wherein it uses a combination of chemical, biological and engineering solutions to create a high quality, cheaper and safer medicines

Global Pharma | 27/06/2022 | By Sudeep Soparkar |  1020

Accenture accelerates data-driven decision-making for Lupin

Develops and deploys an intelligent digital platform that will support growth and innovation

Global Pharma | 22/06/2022 | By Sudeep Soparkar |  704

Ethiopian Ambassador and FDA Director General opens Cadila's formulation lab

A high-level delegation of the Ethiopian Food and Drug Administration visited Cadila’s plant and office

Global Pharma | 21/06/2022 | By Sudeep Soparkar |  582

Global pharma market drives innovative digitalisation to accelerate drug discovery

The global pharmaceuticals market, including small molecules and biologics, is expected to register 3.8 per cent growth, garnering $1.48 trillion by the end of 2022

Global Pharma | 16/06/2022 | By Sudeep Soparkar |  736

DE Shaw Research in license agreement with Eli Lilly and Company

Lilly will make an initial payment of $60 million to DESRES, with potential development and commercial milestone payments of up to $475 million, as well as royalties on worldwide sales

Global Pharma | 15/06/2022 | By Sudeep Soparkar |  2384

Palette Life Sciences bags US FDA approval for Barrigel rectal spacer

The spacer protects prostate cancer patients during radiation therapy

Global Pharma | 13/06/2022 | By Sudeep Soparkar |  1193

Myovant Sciences and Accord Healthcare to commercialize ORGOVYX in Europe

“We are proud to launch ORGOVYX in Europe, as an addition to our specialty brand offerings,” said Binish Chudgar, Managing Director of Accord.

Global Pharma | 12/05/2022 | By Content editor |  753

New biotech Kelonia launched

Kelonia Therapeutics is the newest biotech to hit the pharma scene after receiving $50 million in start-up money.

Global Pharma | 30/04/2022 | By Sudeep Soparkar |  807

Phosplatin with NIH start patient dosing in stage 2 preliminary of PT-112

Phosplatin Therapeutics Inc., a clinical stage pharmaceutical company, announced the first patient has been treated in a phase 2 clinical trial of the company's lead therapeutic candidate, PT-112, in patients with recurrent thymic epithelial tumours (TETs), specifically thymoma and thymic carcinoma.

Global Pharma | 15/04/2022 | By Sudeep Soparkar |  260

Kyttaro and Lily come together to get license deal

UK-based startup Kyttaro and Eli Lilly have announced a new licensing deal.

Global Pharma | 14/04/2022 | By Sudeep Soparkar |  1043